Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Status:
Terminated
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety and efficacy of duvelisib administered in combination with
rituximab vs placebo in combination with rituximab in patients with previously treated
CD20-positive follicular lymphoma who are not suitable candidates for chemotherapy.